Saltar al contenido principal

ETHNOS_APP

Inicio • Búsqueda • Revistas • Lista 0

Huimei An

Datos Biográficos

ID7956558
NOMBREHuimei An
NOMBRESHuimei
APELLIDOAn
FIRMAAN H
AFILIACIONESPeking University
ORCID0000-0002-4749-9430
VERIFICADOSí
TOTAL DE OBRAS8
TOTAL DE CITAS0
TOTAL COMO AUTOR8
TOTAL COMO EDITOR0
PRIMER AÑO DE PUBLICACIÓN2021
AÑO MÁS RECIENTE DE PUBLICACIÓN2025
ÍNDICE H0
  • Sex differences in the prevalence and risk factors of non-suicidal self-injury behaviors among adolescent outpatients with major depressive disorder

    Open Access•Guangyou Lv, Botao Ma et al.•ARTICLE•Frontiers in Psychiatry•2025

    NSSI is more prevalent in female adolescent outpatients with MDD than male outpatients with MDD. Further, there are significant sex differences in the risk factors associated with NSSI, suggesting that sex differences should be considered when developing prevention and intervention strategies for coexisting NSSI behaviors among adolescent outpatients with MDD

  • Association between homocysteine levels and cognition in late-life depression

    Open Access•Ning Fan, Qi Zhang et al.•ARTICLE•Frontiers in Psychiatry•2025

    Patients with LLD often exhibit cognitive impairment and elevated Hcy levels. Notably, the association between Hcy and cognitive function is influenced by the patients' baseline cognitive status. This study offers novel insights into the mechanisms underlying cognitive impairment in patients with depression

  • Homocysteine levels in first-episode patients with psychiatric disorders

    Open Access•Ning Fan, Wenxuan Zhao et al.•ARTICLE•Frontiers in Psychiatry•2024

    A high homocysteine (Hcy) level is a risk factor for schizophrenia, depression, and bipolar disorder. However, the role of hyperhomocysteinemia as either an independent factor or an auxiliary contributor to specific psychiatric symptoms or disorders remains unclear. This study aimed to examine Hcy levels in first-episode inpatients with psychotic symptoms and various psychiatric diseases to elucidate the association between Hcy levels and psychia…

  • Effects of smoking cessation on plasma clozapine concentrations in male patients with schizophrenia during the Covid-19 pandemic

    Open Access•Botao Ma, Hongzhen Fan et al.•ARTICLE•Frontiers in Psychiatry•2023

    The results suggested that clinicians and pharmacists should adjust the CLO dose based on changes in smoking status in patients stabilized with CLO during the COVID-19 pandemic. Careful TDM for CLO should be performed prior to dose adjustment,to reduce the increased risk of smoking cessation induced side effects, especially for older patients receiving multiple medications

  • Relationship Between Plasma Olanzapine and N-Desmethyl-Olanzapine Concentration and Metabolic Parameters in Patients With Schizophrenia

    Open Access•Huimei An, Hongzhen Fan et al.•ARTICLE•Frontiers in Psychiatry•2022

    These results demonstrate that OLA and its metabolite DMO may have different effects on OLA-induced metabolic abnormalities. DMO might have a counteracting effects on glucose-insulin homeostasis and lipid metabolic abnormalities, which suggests that regular measure of various metabolic parameters and drug monitoring on both OLA and DMO are recommended in OLA-treated patients with schizophrenia

  • Subcortical Brain Volumes Relate to Neurocognition in First-Episode Schizophrenia, Bipolar Disorder, Major Depression Disorder, and Healthy Controls

    Open Access•Jing Shi, Hua Guo et al.•ARTICLE•Frontiers in Psychiatry•2022

    The different degrees of subcortical volume lessening may contribute to the differences in cognitive impairment among the three psychiatric disorders

  • High-Dose Betahistine Improves Cognitive Function in Patients With Schizophrenia

    Open Access•Yongqian Wang, Xu-Feng Huang et al.•ARTICLE•Frontiers in Psychiatry•2021

    Background: There is currently no effective treatment for cognitive impairment associated with schizophrenia (CIAS). Recent studies have shown that increased histamine levels in the brain may help to improve CIAS symptoms. Betahistine is an H1-receptor agonist and H3-receptor antagonist. This study evaluated the effect of high-dose betahistine on cognitive function as well as its safety in Chinese Han patients with schizophrenia. Methods: This ra…

  • Gut Microbiome Composition Associated With Major Depressive Disorder and Sleep Quality

    Open Access•Qi Zhang, Yajun Yun et al.•ARTICLE•Frontiers in Psychiatry•2021

    The microbiota-gut-brain axis plays a critical role in the pathogenesis of major depressive disorder (MDD) and related subclinical symptoms. However, studies on the gut microbiota in MDD are inconsistent, and data on MDD's effects on sleep are lacking. This study aimed to analyze the gut microbiota composition and sleep quality of patients with MDD. We performed 16S rRNA sequencing of stool samples from 36 patients with MDD and 45 healthy control…

Sin obras prominentes en esta página.

  • High-Dose Betahistine Improves Cognitive Function in Patients With Schizophrenia

    Open Access•Yongqian Wang, Xu-Feng Huang et al.•ARTICLE•Frontiers in Psychiatry•2021

    Background: There is currently no effective treatment for cognitive impairment associated with schizophrenia (CIAS). Recent studies have shown that increased histamine levels in the brain may help to improve CIAS symptoms. Betahistine is an H1-receptor agonist and H3-receptor antagonist. This study evaluated the effect of high-dose betahistine on cognitive function as well as its safety in Chinese Han patients with schizophrenia. Methods: This ra…

  • Gut Microbiome Composition Associated With Major Depressive Disorder and Sleep Quality

    Open Access•Qi Zhang, Yajun Yun et al.•ARTICLE•Frontiers in Psychiatry•2021

    The microbiota-gut-brain axis plays a critical role in the pathogenesis of major depressive disorder (MDD) and related subclinical symptoms. However, studies on the gut microbiota in MDD are inconsistent, and data on MDD's effects on sleep are lacking. This study aimed to analyze the gut microbiota composition and sleep quality of patients with MDD. We performed 16S rRNA sequencing of stool samples from 36 patients with MDD and 45 healthy control…

  • Relationship Between Plasma Olanzapine and N-Desmethyl-Olanzapine Concentration and Metabolic Parameters in Patients With Schizophrenia

    Open Access•Huimei An, Hongzhen Fan et al.•ARTICLE•Frontiers in Psychiatry•2022

    These results demonstrate that OLA and its metabolite DMO may have different effects on OLA-induced metabolic abnormalities. DMO might have a counteracting effects on glucose-insulin homeostasis and lipid metabolic abnormalities, which suggests that regular measure of various metabolic parameters and drug monitoring on both OLA and DMO are recommended in OLA-treated patients with schizophrenia

  • Subcortical Brain Volumes Relate to Neurocognition in First-Episode Schizophrenia, Bipolar Disorder, Major Depression Disorder, and Healthy Controls

    Open Access•Jing Shi, Hua Guo et al.•ARTICLE•Frontiers in Psychiatry•2022

    The different degrees of subcortical volume lessening may contribute to the differences in cognitive impairment among the three psychiatric disorders

  • Effects of smoking cessation on plasma clozapine concentrations in male patients with schizophrenia during the Covid-19 pandemic

    Open Access•Botao Ma, Hongzhen Fan et al.•ARTICLE•Frontiers in Psychiatry•2023

    The results suggested that clinicians and pharmacists should adjust the CLO dose based on changes in smoking status in patients stabilized with CLO during the COVID-19 pandemic. Careful TDM for CLO should be performed prior to dose adjustment,to reduce the increased risk of smoking cessation induced side effects, especially for older patients receiving multiple medications

  • Homocysteine levels in first-episode patients with psychiatric disorders

    Open Access•Ning Fan, Wenxuan Zhao et al.•ARTICLE•Frontiers in Psychiatry•2024

    A high homocysteine (Hcy) level is a risk factor for schizophrenia, depression, and bipolar disorder. However, the role of hyperhomocysteinemia as either an independent factor or an auxiliary contributor to specific psychiatric symptoms or disorders remains unclear. This study aimed to examine Hcy levels in first-episode inpatients with psychotic symptoms and various psychiatric diseases to elucidate the association between Hcy levels and psychia…

  • Sex differences in the prevalence and risk factors of non-suicidal self-injury behaviors among adolescent outpatients with major depressive disorder

    Open Access•Guangyou Lv, Botao Ma et al.•ARTICLE•Frontiers in Psychiatry•2025

    NSSI is more prevalent in female adolescent outpatients with MDD than male outpatients with MDD. Further, there are significant sex differences in the risk factors associated with NSSI, suggesting that sex differences should be considered when developing prevention and intervention strategies for coexisting NSSI behaviors among adolescent outpatients with MDD

  • Association between homocysteine levels and cognition in late-life depression

    Open Access•Ning Fan, Qi Zhang et al.•ARTICLE•Frontiers in Psychiatry•2025

    Patients with LLD often exhibit cognitive impairment and elevated Hcy levels. Notably, the association between Hcy and cognitive function is influenced by the patients' baseline cognitive status. This study offers novel insights into the mechanisms underlying cognitive impairment in patients with depression

Psychiatry (7 obras) · Internal Medicine (6 obras) · Medicine (6 obras) · Depression (economics (5 obras) · Schizophrenia (object-oriented programming (5 obras) · Psychology (4 obras) · Schizophrenia research and treatment (4 obras) · Cognition (3 obras) · Major depressive disorder (3 obras) · Bipolar disorder (2 obras)

Ethnos_APP • Proyecto Open Source • Licencia MIT • Frontend v2.0.0 • Privacidad y Cookies • Documentación de la API: api.ethnos.app/docs • Código de la API: GitHub • DOI: 10.5281/zenodo.17049435 • Código del Frontend: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae